持田製薬の株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2024/04/26 | 3,145 | 3,145 | 3,090 | 3,145 | +30 | +1% | 90,700 |
2024/04/25 | 3,145 | 3,145 | 3,110 | 3,115 | -40 | -1.3% | 25,000 |
2024/04/24 | 3,160 | 3,165 | 3,145 | 3,155 | -10 | -0.3% | 20,200 |
2024/04/23 | 3,150 | 3,165 | 3,135 | 3,165 | +15 | +0.5% | 20,400 |
2024/04/22 | 3,120 | 3,160 | 3,120 | 3,150 | +60 | +1.9% | 16,500 |
2024/04/19 | 3,105 | 3,120 | 3,060 | 3,090 | -25 | -0.8% | 33,300 |
2024/04/18 | 3,115 | 3,130 | 3,105 | 3,115 | +10 | +0.3% | 12,700 |
2024/04/17 | 3,125 | 3,140 | 3,105 | 3,105 | -40 | -1.3% | 30,000 |
2024/04/16 | 3,115 | 3,145 | 3,115 | 3,145 | -20 | -0.6% | 27,200 |
2024/04/15 | 3,125 | 3,165 | 3,115 | 3,165 | ±0 | ±0% | 26,700 |
2024/04/12 | 3,145 | 3,165 | 3,130 | 3,165 | +35 | +1.1% | 32,300 |
2024/04/11 | 3,100 | 3,140 | 3,090 | 3,130 | -10 | -0.3% | 18,700 |
2024/04/10 | 3,120 | 3,140 | 3,115 | 3,140 | +5 | +0.2% | 14,900 |
2024/04/09 | 3,170 | 3,170 | 3,120 | 3,135 | -10 | -0.3% | 16,800 |
2024/04/08 | 3,135 | 3,145 | 3,110 | 3,145 | +10 | +0.3% | 31,400 |
2024/04/05 | 3,095 | 3,140 | 3,090 | 3,135 | +25 | +0.8% | 27,800 |
2024/04/04 | 3,110 | 3,115 | 3,085 | 3,110 | ±0 | ±0% | 41,800 |
2024/04/03 | 3,120 | 3,140 | 3,095 | 3,110 | -25 | -0.8% | 38,400 |
2024/04/02 | 3,200 | 3,200 | 3,125 | 3,135 | -65 | -2% | 41,700 |
2024/04/01 | 3,220 | 3,230 | 3,190 | 3,200 | -20 | -0.6% | 19,100 |
2024/03/29 | 3,180 | 3,220 | 3,180 | 3,220 | +25 | +0.8% | 26,200 |
2024/03/28 | 3,250 | 3,260 | 3,180 | 3,195 | -95 | -2.9% | 37,900 |
2024/03/27 | 3,260 | 3,305 | 3,260 | 3,290 | +55 | +1.7% | 41,800 |
2024/03/26 | 3,235 | 3,245 | 3,215 | 3,235 | ±0 | ±0% | 22,500 |
2024/03/25 | 3,265 | 3,290 | 3,235 | 3,235 | -50 | -1.5% | 28,100 |
2024/03/22 | 3,290 | 3,290 | 3,235 | 3,285 | -5 | -0.2% | 28,600 |
2024/03/21 | 3,310 | 3,315 | 3,285 | 3,290 | ±0 | ±0% | 21,700 |
2024/03/19 | 3,270 | 3,305 | 3,260 | 3,290 | +15 | +0.5% | 30,700 |
2024/03/18 | 3,270 | 3,280 | 3,260 | 3,275 | +25 | +0.8% | 19,600 |
2024/03/15 | 3,175 | 3,255 | 3,175 | 3,250 | +65 | +2% | 37,800 |
2024/03/14 | 3,185 | 3,195 | 3,150 | 3,185 | +15 | +0.5% | 27,600 |
2024/03/13 | 3,190 | 3,190 | 3,155 | 3,170 | -20 | -0.6% | 23,000 |
2024/03/12 | 3,195 | 3,195 | 3,155 | 3,190 | -5 | -0.2% | 24,600 |
2024/03/11 | 3,230 | 3,240 | 3,160 | 3,195 | -75 | -2.3% | 29,600 |
2024/03/08 | 3,240 | 3,320 | 3,240 | 3,270 | +25 | +0.8% | 78,900 |
2024/03/07 | 3,275 | 3,275 | 3,230 | 3,245 | -15 | -0.5% | 28,600 |
2024/03/06 | 3,225 | 3,285 | 3,225 | 3,260 | +35 | +1.1% | 34,500 |
2024/03/05 | 3,230 | 3,230 | 3,190 | 3,225 | -10 | -0.3% | 45,900 |
2024/03/04 | 3,240 | 3,265 | 3,205 | 3,235 | -5 | -0.2% | 24,200 |
2024/03/01 | 3,270 | 3,270 | 3,225 | 3,240 | -30 | -0.9% | 16,900 |
2024/02/29 | 3,295 | 3,295 | 3,255 | 3,270 | -20 | -0.6% | 40,300 |
2024/02/28 | 3,265 | 3,300 | 3,265 | 3,290 | +10 | +0.3% | 28,100 |
2024/02/27 | 3,230 | 3,300 | 3,230 | 3,280 | +40 | +1.2% | 46,100 |
2024/02/26 | 3,235 | 3,240 | 3,215 | 3,240 | +40 | +1.3% | 35,500 |
2024/02/22 | 3,180 | 3,205 | 3,170 | 3,200 | +20 | +0.6% | 35,200 |
2024/02/21 | 3,190 | 3,210 | 3,160 | 3,180 | -10 | -0.3% | 27,600 |
2024/02/20 | 3,175 | 3,210 | 3,175 | 3,190 | +15 | +0.5% | 22,600 |
2024/02/19 | 3,120 | 3,175 | 3,120 | 3,175 | +55 | +1.8% | 20,600 |
2024/02/16 | 3,105 | 3,145 | 3,095 | 3,120 | +50 | +1.6% | 44,800 |
2024/02/15 | 3,200 | 3,200 | 3,055 | 3,070 | -105 | -3.3% | 107,200 |
1~
50
件表示中 / 3445件
類似銘柄と比較する
現在ご覧いただいている「持田薬」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
持田薬 | 314,500円 | -1.2% | -37.3% | 2.54% | 25.34倍 | 0.88倍 |
|
医薬中堅。高脂血症薬、降圧薬など循環器系得意。婦人科系にも強み。消化器系育成。化粧品も |
ジーエヌアイ | 251,000円 | +52.1% | +23.3% | 0.00% | 17.74倍 | 3.70倍 |
|
創薬ベンチャー。米国で人工骨も。中国の特発性肺線維症薬で高シェア、米中に研究開発機能 |
杏林製薬 | 182,800円 | +2.6% | +11.5% | 2.84% | 21.43倍 | 0.83倍 |
|
医薬中堅。柱のぜんそく薬、呼吸器アレルギー薬は下期に比重。消化器領域育成。後発品も |
鳥居薬 | 385,500円 | +7.3% | +16.8% | 3.11% | 23.06倍 | 0.90倍 |
|
JT傘下。自社製品の腎・透析、アレルゲン等の開発強化。柱の抗HIV薬の販売権喪失が直撃 |
ゼリア新薬 | 205,900円 | +6.8% | +18.7% | 2.14% | 12.97倍 | 1.20倍 |
|
製薬中堅。医療用は消化器系中心。滋養強壮剤「ヘパリーゼ」も柱。スイス企業買収で海外展開 |
市場注目の銘柄
チャート関連のコラム